Trial Profile
A prospective, non-randomized, pilot study to evaluate whether natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Interferon beta
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 07 Nov 2015 New trial record